IBI-3032 is a nonpeptide GLP-1 receptor agonist under development at Innovent Biologics Co. Ltd. for the potential treatment of obesity and other metabolic diseases. The company recently reported results of preclinical studies in which pharmacokinetic profiling was performed in vivo in different species, and the candidate’s in vivo efficacy was tested in a murine model with diet-induced obesity.